Skip to main content
. 2019 May 8;17:146. doi: 10.1186/s12967-019-1903-6

Table 1.

Baseline characteristics and risk factors in derivation and validation cohorts

Variable Derivation cohort (n = 700) Validation cohort (n = 194)
Age, years (IQR) 48 (37–63) 49 (38–61)
Male sex, N (%) 435 (62.1) 127 (65.5)
Duration of symptoms, days 1.83 ± 0.79 1.67 ± 0.78
SIRS, N (%) 272 (38.9) 82 (42.3)
Etiology
 Biliary, N (%) 299 (42.7) 74 (38.1)
 Alcohol, N (%) 96 (13.7) 12 (6.2)
 Hypertriglyceridemia, N (%) 37 (5.3) 31 (16.0)
 Idiopathic, N (%) 246 (35.1) 73 (37.6)
 Other, N (%) 22 (3.1) 4 (2)
Laboratory findings
 Hematocrit 0.42 (0.38–0.46) 0.43 (0.39–0.46)
 Platelets (109/L) 197 (158–233) 206 (169–248)
 Prothrombin time, s (IQR) 13.8 (13.1–14.6) 13.7 (13.2–14.5)
 Albumin, g/L (IQR) 36.2 (32.9–39.7) 36.6 (32.7–39.7)
 Bilirubin, mg/dL (IQR) 1.16 (0.79–1.81) 1.11 (0.76–1.75)
 ALT, U/L (IQR) 40 (19–107) 33 (18–91)
 AST, U/L (IQR) 36 (21–85) 33 (23–73)
 Glucose, mg/dL (IQR) 144 (117–193) 139 (112–191)
 BUN, mg/dL (IQR) 13.4 (10.4–17.4) 14.0 (10.6–17.9)
Pleural effusion, N (%) 135 (19.4) 83 (42.8)
Clinical outcomes
 Patients with SAP, N (%) 68 (9.7) 18 (9.3)
 Number of POF, N (%)
  One organ failure 38/68 (55.9) 7/18 (38.9)
  Two organ failure 19/68 (27.9) 6/18 (33.3)
  Three organ failure 11/68 (16.2) 5/18 (27.8)
 Type of POF
  Respiratory failure, N (%) 56/68 (82.4) 16/18 (88.9)
  Renal failure, N (%) 24/68 (35.3) 10/18 (55.6)
  Cardiovascular failure, N (%) 29/68 (42.7) 8/18 (44.4)
Length of hospital stay, days (IQR) 10 (7–9) 11 (7–17)
 Hospital mortality, N (%) 11 (1.6) 2 (1.0)

Data were mean ± standard deviation, or numbers and percentages, or median (25th–75th percentile), as appropriate

N, number; IQR, interquartile range; BMI, body mass index; SIRS, systemic inflammatory response syndrome; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; SAP, severe acute pancreatitis; POF, persistent organ failure